Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Flonase Switch Application Coming? Actual-Use Study Underway

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline is actively considering the switch potential for Flonase with a trial evaluating consumers' ability to use the allergy nasal spray appropriately, according to the firm

You may also be interested in...



Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough

The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29

Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough

The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29

Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough

The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel